Professor Laurence Albiges is a medical oncologist and head of the Department of Oncology at Gustave Roussy.

Her main areas of interest are new therapies for metastatic kidney cancer and rare forms of renal cell carcinoma. She is currently developing translational research programs on these topics. Laurence Albiges is the author of numerous publications in recognized scientific journals. She is associate editor of the journal European Urology Oncology.

As a result of her research work, she has received several distinctions, awards and funding, including the Conquer Cancer Foundation Merit Award at the ASCO Genitourinary Symposium in 2015 and the Unicancer-Fondation de France grant. Her research on biomarkers of response to immunotherapy is funded by a K-RTP award.

Prof. Laurence Albiges is a member of the GETUG steering committee and of the EAU (European Association of Urology) guidelines panel for kidney cancer. She is involved in the ESMO (European Society for Medical Oncology) where she has been a member of the scientific committee of the congress since 2017. She belongs to the cancer committee of the French association of urology. She belongs to the scientific board of the EIKCS (European International Kidney Cancer Symposium) and EMUC (European Multidisciplinary Congress on Urological Cancers). She is a member of the scientific board of the KCA (Kidney Cancer Association).

Prof. Laurence Albiges has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Astellas, BMS, Eisai, Ipsen, Janssen, Merck, MSD, Novartis, Pfizer, Roche